EP1951394A1 - A method of chromatography using semi-synthetic heparin ligands - Google Patents
A method of chromatography using semi-synthetic heparin ligandsInfo
- Publication number
- EP1951394A1 EP1951394A1 EP06813017A EP06813017A EP1951394A1 EP 1951394 A1 EP1951394 A1 EP 1951394A1 EP 06813017 A EP06813017 A EP 06813017A EP 06813017 A EP06813017 A EP 06813017A EP 1951394 A1 EP1951394 A1 EP 1951394A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- heparin
- ligands
- semi
- separation matrix
- sulfation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Definitions
- the present invention relates to isolation and purification of heparin-binding compounds, such as coagulation factors. More specifically, the invention relates to a method of chromatography, wherein a novel chromatography ligand is used. The invention also embraces a method of preparing a separation matrix that comprises such ligands; a chromatography column comprising the separation matrix and the use thereof.
- a suitable expression system must be designed, including a vector capable of carrying the DNA sequence and a host cell capable of expressing the DNA at sufficiently high levels.
- an efficient purification scheme is required, which needs to be adapted to the specific contaminants present in each expression system. For example, if animal host cells are used, residues such as traces of virus or prions will constitute a potential risk of serious contamination. For safety reasons, the approving authorities in most countries have set levels of acceptable contamination levels which are either very low or zero.
- chromatography Due to its versatility and sensitivity to the target compounds, chromatography is involved as at least one step in many currently used biotech purification schemes.
- the term chromatography embraces a family of closely related separation methods, which are all based on the principle that two mutually immiscible phases are brought into contact. More specifically, the target compound is introduced into a mobile phase, which is con- tacted with a stationary phase. The target compound will then undergo a series of interactions between the stationary and mobile phases as it is being carried through the sys- tern by the mobile phase. The interactions exploit differences in the physical or chemical properties of the components of the sample.
- the stationary phase in chromatography is comprised of a solid carrier to which ligands, which are functional groups capable of interaction with the target compound, have been coupled. Consequently, the ligands will impart to the carrier the ability to effect the separation, identification, and/or purification of molecules of interest.
- Liquid chromatography methods are commonly named after the interaction principle utilised to separate compounds. For example, ion exchange chromatography is based on charge-charge interactions; hydrophobic interaction chromatography (HIC) utilises hydrophobic interactions; and affinity chromatography is based on specific biological affinities.
- proteins are chargeable at certain pH values and can hence be purified using ion exchange chromatography.
- Other chromatographic techniques such as HIC, thiophilic chromatography and immobilised metal affinity chromatography (IMAC) are also useful to this end.
- IMAC immobilised metal affinity chromatography
- affinity chromatography wherein a mechanism sometimes denoted lock/key interaction is utilised.
- affinity chromatography a highly specific biological affinity between two compounds is utilised, such as presented between an antibody and its antigen; between an enzyme and its receptor; and between other ligand and receptor pairs, such as biotin/avidin.
- a large number of biotech products are currently purified by chromatography using as ligand their native receptor.
- antibody products may be purified by affinity chromatography using their respective antigen as a ligand immobilised to a suitable carrier.
- affinity matrix may contain residues of biological substances normally or exceptionally present in the animal tissues such as viruses or prions.
- ligand leakage and contamination are commonly overcome by introducing further downstream purification step(s) that target the potentially leaked ligand or contaminant.
- trace amounts may still be present, and as indicated above, the drag approval authorities these days apply extremely strict limits.
- An alternative way of overcoming the problem is to avoid altogether the use of ligands that involve such risk of contamination.
- organic compounds or smaller synthetic peptides will often be preferred options to protein ligands.
- an alternative solution is to provide a recombinant expression system, such as a bacterial host cell system which is known to be safe.
- expressing a complex protein in a bacterial host will commonly result in a product that differs slightly from the original, for example in terms of folding and glycosylation levels.
- DNA-binding proteins form an extremely diverse class of proteins sharing a single characteristic, namely their ability to bind to DNA.
- they can be produced as fusion proteins comprising a tag sequence fused to that coding for the protein of interest.
- tagging is a time-consuming and costly technology, which since it always involves the addition of a foreign material to the target protein will include potential risks associated to that material.
- group specific affinity chromatography using heparin as a ligand has proved to be an alternative way to go.
- Heparin which is a highly sulphated glycosaminoglycan, has also been shown to have the ability to bind a wide range of other biomolecules, and therefore heparin affinity chromatography is also used to purify other proteins of medical interest such as coagulation factors.
- Heparin occurs in nature as a mixture of chains consisting of repeating disacchari.de units formed by an uronic acid (L-iduronic acid or D-glucuronic acid) and by an amino sugar (glucosamine), joined by ⁇ -l-» 4 or ⁇ -1— >• 4 bonds.
- the uronic acid unit may be sulphated in position 2 and the glucosamine unit is N-acetylated or N-sulphated and 6-0 sulphated.
- Heparin is a polydisperse copolymer with a molecular weight ranging from about 3,000 to about 30,000 Dalton.
- WO 01/02597 (Petrucci et al.) relates to a process of preparing the polysaccharides K4 and K5, which are responsible for extra-intestinal infections.
- the polysaccharides are obtained from Escherichia coli by fermentation, wherein an aqueous medium comprising defatted soy flour, mineral salts and glucose is used as the culture medium.
- the advantage of the disclosed process is stated to reside in the yields obtained.
- further modified K4 and K5 polysaccharides have been suggested, see e.g. WO 02/50125 and WO 02/068477.
- Use of the modified K5 polysaccharide in pharmaceutical preparations has also been disclosed, see e.g. WO 02/083155 (angiogenesis) and WO 03/011307 (HIV).
- Heparin affinity ligands are used commercially in separation matrices available from a number of sources, such as HeparinTM Sepharose (GE Healthcare, Uppsala, Sweden); Affi-GelTM (Bio-Rad); and Immobilised Heparin (Pierce).
- said commercial heparin ligand products all contain heparin obtained by extraction from an animal source, also known as extractive heparins, such as porcine heparin.
- WO 95/05400 Minnesota Mining and Manufacturing Company relates to an improved method of providing heparin functional affinity supports, wherein a heparin functional polymer that comprises biologically active heparin is bonded to a hydrazide reactive group formed from reaction of hydrazine with an azlactone-functional polymer.
- the stated advantages of the affinity support so prepared are a high binding efficiency, a stable coupling linkage and the mild reaction conditions used in its preparation.
- the term "heparin functional polymer" as used in WO 95/05400 includes natural heparins i.e. heparins derived from animal sources, various chemical modifications thereof, and synthetic heparin-like molecules.
- the present invention relates to a method of separating and/or isolating one or more heparin-binding compounds which method does not leave any traces of animal origin in the purified product.
- This can be achieved by a method as defined in the appended claims, which comprises to contact the heparin-binding compound(s) with a separation matrix comprising ligands of semi-synthetic origin.
- heparin means herein heparin which has been obtained by expression in a bacterial host system and subsequent chemical and/or enzymatic modification including sulfation.
- eluent means a liquid capable of releasing one or more adsorbed compounds from a separation matrix.
- Eluents conventionally used in liquid chromatography are defined by conditions such as pH and/or conductivity.
- K5 polysaccharide or “polysaccharide K5" refers to the polysaccharide composed of glucuronic acid and N-acetylglucosamine described by W.F. Vann et al., Eur. J. Biochim. 1981, 43, 51-134.
- heparin-binding compound means herein any compound, molecule or other entity capable of binding to heparin and semi-synthetic heparin with a binding strength that allows its separation by liquid chromatography.
- the present invention relates to a method of separating and/or isolating at least one heparin-binding target compound from other component(s) of a liquid, which method comprises
- the liquid from which one or more target compounds are to be separated may be any liquid, and is commonly the liquid wherein the target compound(s) have been manufactured.
- the liquid is a cell lysate or the supernatant of a fermentation broth.
- the cell lysate may have been clarified on beforehand, such as by simple filtration or a preceding step of chromatography.
- the liquid is an unclarified cell lysate.
- the present method may be a capture step, wherein the majority of the target compounds are isolated.
- the present method is an intermediate or polishing step, in which case the mobile phase will include an eluate or flow-through phase originating from a preceding purification step.
- the separation matrix comprising semi- synthetic heparin ligands is provided as described in more detail below, in the context of the second aspect of the invention. It is understood that the term "semi-synthetic heparin ligands" embraces semi-synthetic ligands comprising heparin and functional fragments thereof; as well as fusion proteins comprising any of the above. Thus, the present semi-synthetic heparin ligands are characterised by being able to bind substantially the same target compounds as extractive heparin. In an advantageous embodiment, the semi-synthetic heparin ligands used in the present method exhibit binding capacities substantially equivalent to those of porcine extractive heparin.
- the liquid comprising the target compound(s) is commonly combined with an appropriate buffer wherein conditions such as pH and/or conductivity are controlled.
- Buffers suitable to this end are as a general rule the buffers conventionally recommended as mobile phases for commercial separation matrices comprising extractive heparin ligands.
- the mobile phase comprises a buffer selected from the group consisting of Tris-HCl, EDTA, mercaptoethanol and glycerol.
- the pH of the mobile phase, as it is contacted with the separation matrix is neutral to weakly alkaline, such as in the range of 7-14. In an advantageous embodiment, the pH of the mobile phase is about 8.
- the present method is an affinity chromatography process utilising the specific biological affinity between target and ligand in the adsorption step.
- the method is an ion-exchange process for the purification of negatively charged target compounds wherein charge-charge interactions are utilised in the adsorption step.
- the separation matrix may be provided in the form of porous or non-porous particles, such as substantially spherical beads. Such particles may have an average size in the range of 10-500 ⁇ m, such as in the range of 50-150 ⁇ m. In an advantageous embodiment, the particles exhibit an average particle size of about 90 ⁇ m. In this context, the particle sizes are given as the median particle size of a cumulative volume distribution.
- the separation matrix may be irregularly shaped particles, such as crushed agarose; a monolith; a membrane; a chip; a surface; a capillary; or the like. Suitable materials for making the separation matrix will be discussed in more detail below in the context of the second aspect of the invention.
- the separation matrix may be provided in a chromatography column, commonly as a packed or fluidised bed of particles.
- step (b) is carried out by passing the mobile phase across the separation matrix.
- the flow rate of the mobile phase across the separation matrix is in the range of 50-400 cm/h. This embodiment preferably utilises a column comprising a packed bed of essentially spherical particles.
- step (c) will be included in the present method if the desired product is one or more purified target compounds, while step (c) will be omitted if the desired product is a purified liquid which is substantially devoid of one or more target compounds.
- the present method comprises a step of recovering target compound(s) by adding an eluent to the separation matrix.
- an eluent is understood to be any liquid capable of releasing the adsorbed compound(s) from the matrix.
- the salt concentration is higher in the eluent than in the mobile phase, which means that the target compound is eluted by salt addition, in other words, by an increase in conductivity.
- This elution mode is preferably carried out by adding a gradient of changing salt concentration i.e. an eluent wherein the salt concentration gradually increases.
- a linear gradient is commonly used, such as from 1- 100% of 1.0M of a common salt such as NaCl.
- a step-wise salt gradient is used in the present eluent.
- the target compound may be any heparin-binding compound, cell or molecule.
- the heparin-binding compound is a coagulation factor or a DNA-binding protein.
- the heparin-binding compound may be selected from the group consisting of restriction endonucleases; protein synthesis initiation factors and proteins; serine protease inhibitors, such as anti- thrombin; enzymes, such as lipases; growth factors; and lipoproteins.
- the heparin-binding compound is selected from the group consisting of serum coagulation proteins.
- the present invention relates to a method of preparing a separation matrix by chemical and enzymatic modification of heparin expressed in E. coli.
- the present method comprises to provide semi-synthetic heparin and coupling said heparin to a carrier.
- the method of preparing a separation matrix comprising semi-synthetic heparin ligands comprises i) expression of K5 polysaccharide in bacterial host cells; ii) N-deacetylation of GIcNAc residues of the K5 polysaccharide so obtained, and N-sulfation of resulting amino groups; iii) C5 epimerisation of D-GIcA to L-iduronic acid; iv) sulfation of the epimerised product to provide semi-synthetic heparin ligands; and v) coupling of the ligands from step (d) to a carrier.
- the K5 polysaccharide of step (i) is composed of substantially equimolecular quantities of glucuronic acid and N-acetylglucosamine, which make up the alternate linear repetitive unit 4- ⁇ -glucuronic l,4, ⁇ -N-acetylglucosamine.
- a suitable bacterial host cell is fermented by any well known method, such as submerged culture, to produce the K5 polysaccharide.
- the prokaryotic cells are preferably bacterial cells, such as Escherichia coli.
- the host cells secrete the polysaccharide product into the culture medium.
- coli strains suitable for production of polysaccharide K5 are obtainable from public collections, such as ATCC [American Type Culture Collection] or DSM [Deutsche Sammlung von Microorganismen].
- the present method uses strain E.coli 010:K5:H4, ATCC number 23506, for providing the K5 polysaccharide.
- the K5 polysaccharide is preferably purified according to well known methods.
- a suitable starting amount may be in the range of 5-15 g, such as about 1O g.
- the K5 polysaccharide is, after appropriate purification and conditioning, subjected to N-deace ⁇ ylation and subsequent N-sulfation, which are carried out by methods known per se.
- the GIcNAc residues of the polysaccharide K5 are N-deacetylated by adding sodium hydroxide and reacting at increased temperature such as 40-80 0 C, for an appropriate period of time. The solution is allowed to cool to ambient temperature, and preferably neutralised by adding acid such as hydrochloric acid.
- the subsequent N-sulfation of resulting amino groups is provided by adding a suitable sulfating agent such as pyridine sulfur trioxide or trimethylamine sulfur trioxide and reacting for an appropriate period of time at a slightly increased temperature. Salt is then preferably removed by using any well known technique for desalting a solution.
- a suitable sulfating agent such as pyridine sulfur trioxide or trimethylamine sulfur trioxide
- the C5 epimerisation which is a step of enzymatic treatment, converts D-GIcA to L- iduronic acid. Such epimerisation may be performed in solution or with immobilised enzyme.
- the enzyme glucuronosyl C5 epimerase commonly known as C5 epimerase, is commercially available and methods for epimerisation are well known in this field.
- the sulfation of step (iv) comprises an O-oversulfation carried out by converting the C5 epimerised K5 polysaccharide into a ternary or quaternary salt thereof and treating the salt with an O-sulfation agent according to well known methods.
- the sulfation of step (iv) also comprises a selective O- desulfation carried out according to any well known method.
- a selective O- desulfation carried out according to any well known method. This may e.g. be provided by passing the O-oversulfated product through a cationic exchange resin IR 120 H+; washing of the resin with about 3 volumes of deionised water; and neutralisation with pyridine.
- selective O-desulfation means that the sulfate groups in position 6 of the glucosamine are eliminated first, then the sulfate groups in position 3 and 2 of the uronic acid and finally the sulfate group in position 3 of the amino sugar.
- the present method also comprises a step of 6-O-sulfation of the sulfated product from the preceding step.
- 6-O-sulfation may be carried out as discussed above for O-sulfation.
- the so obtained product is subjected to N-sulfation.
- the semi-synthetic heparin ligands so produced are advantageously purified according to well known methods, such as diaf ⁇ ltration.
- the product is then depolymerised to obtain a suitably sized ligand which still retains its biological activity.
- the semi-synthetic heparin ligand which is immobilised in the subsequent step exhibits a molecular weight of 10,000- 25,000 Dalton, such as about 20,000 Dalton.
- steps (ii)-(iv) of the present method are found e.g. in WO 02/50125.
- the carrier to which the semi-synthetic heparin ligands according to the invention are immobilised may be any suitable porous or non-porous carrier material commonly used in the purification of proteins.
- the carrier is comprised of a cross-linked carbohydrate material, such as agarose, agar, cellulose, starch, pectin, dextran, chitosan, konjac, carrageenan, gellan, alginate etc.
- the carrier can easily be prepared according to standard methods, such as inverse suspension gelation (S Hjerten: Biochim Biophys Acta 79(2), 393-398 (1964).
- the carrier is a commercially available product, such as SepharoseTM FF (GE Healthcare, Uppsala, Sweden).
- the carrier is a cross- linked polysaccharide, such as agarose.
- the agarose has been prepared and/or modified to present an improved rigidity in order to withstand high flow rates, see e.g. US 6,602,990 (Berg).
- the carrier used in the present method is comprised of cross-linked synthetic polymers, such as styrene or styrene derivatives, divinylbenzene, acrylamides, acrylate esters, methacrylate esters, vinyl esters, vinyl amides etc. Carriers made from such polymers are easily produced according to standard methods, see e.g. "Styrene based polymer supports developed by suspension polymerization” (R Arshady: Chimica e L'Industria 70(9), 70-75 (1988)).
- the carrier is a commercially available product, such, as SourceTM (GE Healthcare, Uppsala, Sweden).
- the surface of the carrier is preferably modified to increase its hydrophilicity, usually by converting the majority of the exposed residual double bonds to hydroxyl groups, before allylation and coupling of the semi-synthetic heparin ligands.
- the semi-synthetic heparin ligands are immobilised to the carrier via extenders, or a coating polymer layer.
- extenders also known as “flexible arms”
- the carrier may e.g. be coated with dextran, to provide a hydrophilic nature to the support, to which the semisynthetic heparin ligands are immobilised according to well known methods in this field.
- the coupling of the O-sulfated products from step (iv) may be achieved by immobilisation to a carrier using any well known method.
- the coupling of the semi-synthetic heparin ligands obtained should preferably be alkali stable for an extended period of time.
- the product from the preceding step is coupled to the carrier using reductive amination, as disclosed e.g. in Hermanson et al in "Immobilised Affinity Ligand Techniques", Academic Press Inc. (1992), pp. 69-79, which is hereby included herein via reference.
- the reducing agent is selected from the group consisting OfNaBH 4 and NaCNBH 3 .
- the present invention relates to a separation matrix, which comprises a carrier to which ligands have been coupled, wherein the ligands are bacterially expressed, chemically and enzymatically modified heparin.
- this aspect of the invention is a separation matrix, which comprises semi-synthetic heparin ligands coupled to a carrier.
- the carrier may be as discussed above in the context of the first and second aspects of the invention.
- the separation matrix according to the invention comprises chromatography ligands prepared by expression of K5 polysaccharide in bacterial host cells; deacetylation; sulfation of resulting amino groups, C5 epimer- isation of D-GIcA to L-iduronic acid; and O-sulfation of C2 of IdoA and at C6 of glucosamine units.
- the semi-synthetic heparin ligands have been coupled to the carrier via amine linkages.
- the present matrix has been prepared by the method defined in any one of claims 12-21.
- the present invention also encompasses a chromatography column comprising a separation matrix as described above.
- the column is made from any conventional material, such as biocompatible plastic, e.g. polypropylene, steel, such as stainless steel, or glass.
- the column may be of a size suitable for laboratory scale or large-scale purification.
- the column according to the invention is provided with luer adaptors, tubing connectors, and domed nuts.
- the separation matrix may be packed in the column, or provided as a fluidised bed.
- an additional aspect of the invention is the use of a separation matrix, which comprises a carrier to which semi-synthetic heparin ligands have been coupled, wherein the semi-synthetic heparin ligands comprises bacterially expressed, chemically and en- zymatically modified heparin, in liquid chromatography.
- the semi-synthetic heparin ligands are coupled via amine linkages to the carrier.
- the present use enables a heparin-binding target molecule selected from the group consisting of Factor Xa; Heparin Cofactor II (HCII); and Antithrombin III (ATIII) to be separated and/or isolated.
- a heparin-binding target molecule selected from the group consisting of Factor Xa; Heparin Cofactor II (HCII); and Antithrombin III (ATIII) to be separated and/or isolated.
- HCII Heparin Cofactor II
- ATIII Antithrombin III
- the present invention also encompasses a kit which comprises, in separate compartments, a chromatography column as described above; at least one buffer; and written instructions for purification of heparin-binding target compounds.
- the kit according to the invention may be used e.g. in the medical or diagnostic field.
- Example 1 Manufacture of a separation matrix according to the invention
- the K5 polysaccharide was prepared and modified chemically and enzymatically essentially as described in Casu et al (Carbohydrate Letters, Volume 1, pp. 107-114 (1994): "Biologically Active, Heparan Sulfate-like Species by Combined Chemical and Enzymatic modification of the Escherichia coli Polysaccharide K5").
- pre-activated agarose gel particles article number 17-3092-09 Amino SepharoseTM, GE Healthcare, Uppsala, Sweden
- highly cross-linked 6% agarose were used.
- the K5 polysaccharide was depolymerised to a molecular weight of 20,000 and coupled to the pre-activated carriers via reductive amination. More specifically, 1O g of the pre- activated gel above was first drained, then washed with water and buffer. It was sucked up and transferred to a vial fitted with screw cap. After having shaken the vial, reducing buffer comprising NaCNBH 3 and K5 polysaccharide were added. The reaction mixture was poured onto a glass filter funnel and the functionalised gel so obtained was washed, sucked dry and transferred to an ethanol-containing storage solution.
- Level A (U1154040A): 200 mg of K5 ligand in reaction solution
- Level B (U1154040B): 250 mg of K5 ligand in reaction solution
- Level C (U1154040C): 300 mg of K5 ligand in reaction solution
- Bovine plasma obtained from SVA-Bro, Sweden
- the separation matrix prepared as described in Example 1 was tested on an HR 5/5 column equipped with one LCC-500 control unit, two P-500 pumps, UV-I monitor (280 nm, HR-10 cell), one MV-7 motor valve and four MV-8 motor valves. One 100 mL su- perloop, two 10 mL measuring flasks for each column. The absorbance was measured on an UV- Vis spectrophotometer.
- Buffer A 0.1 M Tris, 0.01 M trisodium citrate, 0.225 M NaCl adjusted to pH 7.4 with
- Buffer B 0.1 M Tris, 0.01 M trisodium citrate, 0.33 M NaCl adjusted to pH 7.4 with
- Buffer C 0.1 M Tris, 0.01 M trisodium citrate, 2.0 M NaCl adjusted to pH 7.4 with
- Bovine plasma from five different cows was pooled and frozen in fractions of 45 niL. Two frozen samples were thawn and filtrated through 0.45 ⁇ m filter (Millipore SVHV 01015) with a peristaltic pump. 80.0 mL of the filtrated plasma was then mixed with 40.0 mL buffer A and poured into a superloop (100 mL, HR 16/50 column tube)
- the column and superloop were connected to the FPLC System.
- the column was equilibrated with 5 mL of buffer A. 45 mL sample was then injected with the superloop. Subsequent washings were performed with 40 mL buffer A and 15 mL buffer B.
- the anti- thrombin (AT III) was eluted from the column with 9 mL buffer C. The eluate was collected in a 10 mL measuring flask which was then filled to the mark with buffer C. The absorbance was measured at 280 nm with buffer C as a blank.
- the binding capacity for AT III is calculated from the formulas listed below.
- R column radius (HR 5/5: 0.25 cm)
- F packing factor (mL drained gel / mL packed gel: 0.934)
- C binding capacity (mg AT III / mL drained gel)
- the factor F is calculated from the results on a reference gel tested with the former plasma (plasma ⁇ and a new batch of plasma (plasma 2 ). The factor is 1.00 for the first plasma batch (plasmao).
- the values found for the commercial product are about 3.0 mg/mL gel with a maximum of 10% difference, usually less than 5%.
- the protein capacity for the three prototypes with the semi-synthetic K5 polysaccharide as ligand showed higher capacity:
- the gel Ul 154040 A presents a capacity 30% higher than the commercial product, while Ul 154040B and Ul 154040C have an AT III capacity of 5.7 and 7.2 mg/mL gel respectively corresponding to more than double the capacity compared to the reference.
- the prototypes with immobilized semi-synthetic heparin present all a higher AT III binding capacity, with more than double the value for gel Ul 154040C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0502569 | 2005-11-21 | ||
PCT/SE2006/001297 WO2007058592A1 (en) | 2005-11-21 | 2006-11-15 | A method of chromatography using semi-synthetic heparin ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1951394A1 true EP1951394A1 (en) | 2008-08-06 |
EP1951394A4 EP1951394A4 (en) | 2011-01-19 |
Family
ID=38048901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06813017A Withdrawn EP1951394A4 (en) | 2005-11-21 | 2006-11-15 | A method of chromatography using semi-synthetic heparin ligands |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1951394A4 (en) |
AU (1) | AU2006316039B2 (en) |
WO (1) | WO2007058592A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2630823C (en) | 2005-12-13 | 2015-02-10 | Exthera Ab | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
AU2008265838A1 (en) * | 2007-06-18 | 2008-12-24 | Exthera Medical Llc | Device and method for restoration of the condition of blood |
FR2942233B1 (en) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | MEANS FOR PURIFYING BLOOD PLASMA PROTEIN, AND METHODS FOR ITS IMPLEMENTATION |
KR101716241B1 (en) | 2009-12-01 | 2017-03-14 | 엑스테라 메디컬 코퍼레이션 | Method for removing cytokines from blood with surface immobilized polysaccharides |
WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
DK2861273T3 (en) | 2012-06-13 | 2017-11-27 | Exthera Medical Corp | Use of heparin and carbohydrates for the treatment of cancer. |
WO2014209782A1 (en) | 2013-06-24 | 2014-12-31 | Exthera Medical Corporation | Blood filtration system containing mannose coated substrate |
CA2928866C (en) | 2013-11-08 | 2021-11-09 | Exthera Medical Corporation | Methods for diagnosing infectious diseases using adsorption media |
JP2017513636A (en) | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | Method for removing bacteria from blood using high flow rate |
KR20170060062A (en) | 2014-09-22 | 2017-05-31 | 엑스테라 메디컬 코퍼레이션 | Wearable hemoperfusion device |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
CN107286271A (en) * | 2017-08-10 | 2017-10-24 | 盐城盛大肠衣食品有限公司 | A kind of resin adsorption extracts liquaemin device |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017910A2 (en) * | 2002-08-23 | 2004-03-04 | Neose Technologies, Inc. | Total synthesis of heparin |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3519011A1 (en) * | 1985-05-25 | 1986-11-27 | Behringwerke Ag, 3550 Marburg | METHOD FOR PRODUCING A MATERIAL FOR AFFINITY CHROMATOGRAPHY |
WO1995005400A1 (en) * | 1993-08-19 | 1995-02-23 | Minnesota Mining And Manufacturing Company | Heparin functional affinity supports |
US20020062019A1 (en) * | 2000-03-30 | 2002-05-23 | Pasqua Oreste | Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation |
IT1318432B1 (en) * | 2000-03-30 | 2003-08-25 | Inalco Spa | GLYCOSAMINOGLICANS DERIVED FROM THE K5 POLYSACCHARIDE HAVING HIGH ANTI-AGULATING AND ANTI-THROMBOTIC ACTIVITY AND PROCESS FOR THEM |
ITMI20031618A1 (en) * | 2003-08-06 | 2005-02-07 | Inalco Spa | POLYSACCHARIDE DERIVATIVES EQUIPPED WITH HIGH ACTIVITY |
-
2006
- 2006-11-15 EP EP06813017A patent/EP1951394A4/en not_active Withdrawn
- 2006-11-15 AU AU2006316039A patent/AU2006316039B2/en not_active Ceased
- 2006-11-15 WO PCT/SE2006/001297 patent/WO2007058592A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004017910A2 (en) * | 2002-08-23 | 2004-03-04 | Neose Technologies, Inc. | Total synthesis of heparin |
Non-Patent Citations (1)
Title |
---|
See also references of WO2007058592A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2006316039A1 (en) | 2007-05-24 |
EP1951394A4 (en) | 2011-01-19 |
WO2007058592A1 (en) | 2007-05-24 |
AU2006316039B2 (en) | 2011-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006316039B2 (en) | A method of chromatography using semi-synthetic heparin ligands | |
EP0046581B1 (en) | Process for separation of mucopolysaccharides | |
EP1729867B1 (en) | A method for chromatographic purification | |
Ringertz et al. | Chromatography on ECTEOLA of sulfate containing mucopolysaccharides | |
Porath et al. | Agar derivatives for chromatography, electrophoresis and gel-bound enzymes: III. Rigid agarose gels cross-linked with divinyl sulphone (DVS) | |
CA2083168C (en) | Adsorbent for cellular fibronectin and a method for fractional purification of fibronectin | |
Flodin et al. | Separation of acidic oligosaccharides by gel filtration | |
US3959251A (en) | Stabilized agar product and method for its stabilization | |
EP0086186A1 (en) | A process for covalent coupling for the production of conjugates, and products hereby obtained | |
KR101215171B1 (en) | Method of Preparing a Chromatography Matrix | |
JP2726275B2 (en) | Purification of glycosaminoglycan degrading enzyme | |
EP0509517B1 (en) | Oligosaccharide having affinity for fibroblast growth factor and process for producing same | |
Zhou et al. | Coated silica supports for high-performance affinity chromatography of proteins | |
Shi et al. | Affinity chromatography of trypsin using chitosan as ligand support | |
IE20000781A1 (en) | Process for the purification of serum albumin | |
Baieli et al. | Efficient wheat germ agglutinin purification with a chitosan‐based affinity chromatographic matrix | |
JPS59149901A (en) | Heparin purification and fractionation | |
CA1283073C (en) | Adsorbent for purification of blood coagulation factor viii and process for purification of blood coagulation factor viii using the same | |
Franco et al. | Characterization of storage cell wall polysaccharides from Brazilian legume seeds and the formation of aqueous two-phase systems | |
Kennedy | Observations on molecular weight discrimination by filtration through porous media | |
JP2001097997A (en) | Carrier for affinity absorption from sulfated hyaluronic acid, and its use | |
Lyon et al. | A rapid purification of bovine testicular hyaluronidase by chromatography on dermatan sulphate-substituted 1, 6-diaminohexane–sepharose 4B | |
CN105399870B (en) | A kind of low-anticoagulant heparin, its oligosaccharide and preparation method thereof and the application in the medicine for preparing anti-alzheimer's disease | |
Chen et al. | Alginate as a displacer for protein displacement chromatography | |
JP2002327001A (en) | Method of selective adsorption for saccharide, particle, compound and cell adhesion factor and method for controlling cancer metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080418 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20101220 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01J 20/26 20060101ALI20101214BHEP Ipc: C07K 1/22 20060101ALI20101214BHEP Ipc: C07K 14/745 20060101ALI20101214BHEP Ipc: C08B 37/10 20060101ALI20101214BHEP Ipc: C12N 9/74 20060101ALI20101214BHEP Ipc: B01D 15/38 20060101ALI20101214BHEP Ipc: C12N 9/64 20060101ALI20101214BHEP Ipc: B01D 15/20 20060101AFI20070718BHEP |
|
17Q | First examination report despatched |
Effective date: 20110110 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130417 |